Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-21,000
Closed -$3.65M 5234
2025
Q4
$3.65M Hold
21,000
﹤0.01% 2468
2025
Q3
$3.02M Buy
+21,000
New +$2.57M ﹤0.01% 2557
2024
Q3
Sell
-68,300
Closed -$4.58M 5373
2024
Q2
$4.58M Buy
68,300
+13,500
+25% +$524K ﹤0.01% 1604
2024
Q1
$1.49M Buy
+54,800
New +$1.53M ﹤0.01% 2805
2020
Q1
Sell
-142,300
Closed -$3.4M 6289
2019
Q4
$3.4M Buy
+142,300
New +$2.89M ﹤0.01% 2429
2019
Q2
Sell
-300
Closed -$9K 7079
2019
Q1
$9K Buy
+300
New +$7.78K ﹤0.01% 6584
2018
Q2
Sell
-100
Closed -$2K 7097
2018
Q1
$2K Buy
+100
New +$2.63K ﹤0.01% 6900
2017
Q4
Sell
-58,700
Closed -$1.83M 6998
2017
Q3
$1.83M Buy
+58,700
New +$1.12M ﹤0.01% 2441
2014
Q2
Sell
-605,000
Closed -$11.5M 7689
2014
Q1
$11.5M Buy
+605,000
New +$11.5M 0.01% 1047

Other funds holding INSM

Barclays's INSM Position: Q1 2026 in Review

Barclays reduced its Insmed (INSM) stake by 38% in Q1 2026, selling an estimated $26M and leaving 275,731 shares worth $45.1M. The position accounts for 0.01% of the portfolio, ranked #765.

Barclays first reported a position in INSM in Q2 2013 and has held it in 51 quarters since. The position peaked at $77.4M in Q4 2025. 669 funds tracked by Wall St. Rank hold INSM as of Q1 2026.

  • Barclays held 275,731 shares of Insmed worth $45.1M as of Q1 2026.
  • Barclays sold 168,975 Insmed shares in Q1 2026, an estimated $26M.
  • Insmed made up 0.01% of Barclays's portfolio in Q1 2026, its #765 holding.
  • Barclays first reported a position in Insmed in Q2 2013 and has held it in 51 quarters since.
  • Barclays's Insmed position peaked at $77.4M in Q4 2025.
  • 669 funds tracked by Wall St. Rank held Insmed as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.